Comparison 2. CQ versus lopinavir/ritonavir for treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Negative PCR for SARS‐CoV‐2 on respiratory samples at day 7 from enrolment	1	22	Risk Ratio (M‐H, Random, 95% CI)	1.20 [0.64, 2.25]
2.2 Negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from enrolment	1	22	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.85, 1.36]
2.3 Discharge from hospital at day 14 from enrolment	1	22	Risk Ratio (M‐H, Random, 95% CI)	1.91 [1.09, 3.34]
2.4 Clinical improvement at day 10 from enrolment	1	22	Risk Ratio (M‐H, Random, 95% CI)	1.37 [0.78, 2.42]
2.5 Total adverse events	1	22	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.78, 1.50]
2.6 Serious adverse events	1	22	Risk Ratio (M‐H, Random, 95% CI)	Not estimable